UBS Defends Momenta Pharmaceuticals (NASDAQ: MNTA); Negative News Largely In Stock
Tweet Send to a FriendGet Alerts MNTA Hot Sheet
Price: $13.29 +0.23%
Rating Summary:
3 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 23 | New: 29
Rating Summary:
3 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 23 | New: 29
Trade MNTA Now!
UBS maintains a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $15.00 (from $18.00).
Analyst, Ami Fadia, noted that NY courts ruled that Mylan (NYSE: MYL)/Natco's and Momenta/Sandoz's New Drug Application (for generic Copaxone) infringed on Teva (Nasdaq: TEVA), the patent holder for Copaxone. The ruling prevents generics from launching an OB-listed drug until patent expiration on May 24, 2014. Teva thinks the process may delay generics further (until Sept 2015)
Fadia had expected a TEVA victory, but though Momenta would be able to submit generic in 2014. Because there is a possible delay until Sept 2015, Fadia lowers estimates on MNTA for 2012 from (1.10) to (1.11) and FY13 from (1.18) to (1.22).
She concluded by saying, "Further, we believe Teva will switch ~35% of the mkt to the new version before generics enter. Accordingly, we are lowering our peak sales estimate for generic Copaxone from ~$400M to $300M in 2017 for Momenta. This resulted in an EPS impact of -$1.27 in 2.014E, -$1.72 in 2015E and -$0.54 in 2016E."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $13.20 yesterday, with a 52 week range of $10.15-$21.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ami Fadia, noted that NY courts ruled that Mylan (NYSE: MYL)/Natco's and Momenta/Sandoz's New Drug Application (for generic Copaxone) infringed on Teva (Nasdaq: TEVA), the patent holder for Copaxone. The ruling prevents generics from launching an OB-listed drug until patent expiration on May 24, 2014. Teva thinks the process may delay generics further (until Sept 2015)
Fadia had expected a TEVA victory, but though Momenta would be able to submit generic in 2014. Because there is a possible delay until Sept 2015, Fadia lowers estimates on MNTA for 2012 from (1.10) to (1.11) and FY13 from (1.18) to (1.22).
She concluded by saying, "Further, we believe Teva will switch ~35% of the mkt to the new version before generics enter. Accordingly, we are lowering our peak sales estimate for generic Copaxone from ~$400M to $300M in 2017 for Momenta. This resulted in an EPS impact of -$1.27 in 2.014E, -$1.72 in 2015E and -$0.54 in 2016E."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $13.20 yesterday, with a 52 week range of $10.15-$21.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- Wedbush Expects Positive Results from Insmed (INSM) ARIKAC Trial
- Needham & Company Maintains Underpform on HP (HPQ), Says Positives Priced In
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDARelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
